Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 6/20 | 0.38 |
| ▸ | KDM1A | O60341 | 4/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 6/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 5/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 5/20 | 0.35 |
| ▸ | KDR | P35968 | 5/20 | 0.35 |
| ▸ | FLT3 | P36888 | 3/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5210532 | 0.92 | FGFR1 (0.40) | FGFR1FGFR3FGFR2FGFR4KDR | |
| SCHEMBL5210909 | 0.87 | KDM1A (0.37) | FGFR1KDM1AFGFR3FGFR2FGFR4 | |
| SCHEMBL5207852 | 0.87 | FYN (0.43) | — | |
| SCHEMBL5204509 | 0.86 | KDM1A (0.46) | FGFR1KDM1AFGFR3FGFR2FGFR4 | |
| SCHEMBL5207615 | 0.86 | SMPD3 (0.41) | — | |
| SCHEMBL5208946 | 0.86 | PDGFRB (0.37) | KDM1APDGFRBPDGFRADOT1L | |
| SCHEMBL5204558 | 0.84 | FYN (0.40) | — | |
| SCHEMBL5205364 | 0.84 | MEN1 (0.41) | — | |
| SCHEMBL5205794 | 0.84 | KDM1A (0.34) | KDM1APDGFRBPDGFRA | |
| SCHEMBL5206832 | 0.83 | KDM4E (0.38) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1403251-B1 | BIS(2-ARYL-5-PYRIDYL) DERIVATIVE | KOWA CO (JP) | 2007-07-18 | — | — | EP | disclosed |
| US-6890940-B2 | Bis(2-aryl-5-pyridyl) derivatives | KOWA CO., LTD. (JP) | 2005-05-10 | — | — | US | disclosed |
| EP-1403251-A1 | BIS(2-ARYL-5-PYRIDYL) DERIVATIVE | Kowa Co., Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-20030022886-A1 | Immoglobulin E (IgE) antibody production inhibitor; treating allergic immune diseases such as asthma, dermatitis, inflammatory bowel disease and allergic opthalmopathy | KOWA CO., LTD. (JP) | 2003-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022886-A1 | Immoglobulin E (IgE) antibody production inhibitor; treating allergic immune diseases such as asthma, dermatitis, inflammatory bowel disease and allergic opthalmopathy | IGLV6-57, IL5, IGSF11 | FGFR1 548/4885KDM1A 2363/4885FGFR3 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.